Davis-based cancer drug startup aims to raise $2.7 million


CEO Lonnie Bookbinder says the startup is part of a larger effort to commercialize research coming out of the University of California Davis.

Previous ​Tough fourth quarter casts shadow over Wall St bonuses
Next Stapleton retail site sells to Evergreen Devco for $11.45 per square foot